Arbutus Biopharma (ABUS) Total Liabilities (2010 - 2026)

Arbutus Biopharma (ABUS) has reported Total Liabilities for 17 consecutive years, with $17.0 million the latest figure, recorded in Q1 2026.

• Quarterly Total Liabilities fell 55.12% year-over-year to $17.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.0 million (down 55.12% YoY) and the FY2025 annual result came in at $18.0 million, down 47.46% from the prior year.
• Total Liabilities slipped to $17.0 million in Q1 2026 per ABUS's latest filing, from $18.0 million in the prior quarter.
• Over the last five years, Total Liabilities for ABUS reached as high as $71.0 million in Q1 2022 and fell as low as $17.0 million in Q1 2026.
• A 5-year average of $39.5 million and a median of $37.9 million in 2025 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2022 — Total Liabilities jumped 121.35% — and 2026, when it slumped 55.12%.
• Year by year, Total Liabilities stood at $58.6 million in 2022, then slumped by 34.46% to $38.4 million in 2023, then dropped by 10.53% to $34.3 million in 2024, then sank by 47.46% to $18.0 million in 2025, then declined by 5.85% to $17.0 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $17.0 million, $18.0 million, and $20.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.